PDT Partners’s NovoCure NVCR Stock Holding History

PDT Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$337K	Hold	22,252	–	–	0.02%	433
2026 Q1	$243K	Hold	22,252	–	–	0.01%	478
2025 Q4	$288K	Buy	+22,252	New	+$286K	0.02%	483
2025 Q3	–	Sell	-21,558	Closed	-$384K	–	684
2025 Q2	$384K	Buy	+21,558	New	+$376K	0.02%	558
2025 Q1	–	Sell	-80,232	Closed	-$2.39M	–	823
2024 Q4	$2.39M	Sell	80,232 -31,851	-28%	-$674K	0.21%	165
2024 Q3	$1.75M	Sell	112,083 -76,339	-41%	-$1.38M	0.16%	239
2024 Q2	$3.23M	Buy	188,422 +100	+0.1%	+$1.76K	0.31%	96
2024 Q1	$2.94M	Buy	188,322 +163,550	+660%	+$2.41M	0.28%	114
2023 Q4	$370K	Buy	+24,772	New	+$332K	0.04%	442
2020 Q3	–	Sell	-14,430	Closed	-$856K	–	817
2020 Q2	$856K	Buy	+14,430	New	+$949K	0.06%	307

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

PDT Partners's NVCR Position: Q2 2026 in Review

PDT Partners held its NovoCure (NVCR) position steady in Q2 2026 at 22,252 shares worth $337K. The position accounts for 0.02% of the portfolio, ranked #433.

PDT Partners first reported a position in NVCR in Q2 2020 and has held it in 10 quarters since. The position peaked at $3.23M in Q2 2024. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

PDT Partners held 22,252 shares of NovoCure worth $337K as of Q2 2026.
PDT Partners left its NovoCure share count unchanged in Q2 2026.
NovoCure made up 0.02% of PDT Partners's portfolio in Q2 2026, its #433 holding.
PDT Partners first reported a position in NovoCure in Q2 2020 and has held it in 10 quarters since.
PDT Partners's NovoCure position peaked at $3.23M in Q2 2024.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.